These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3931154)

  • 1. Scopolamine challenges in Alzheimer's disease.
    Sunderland T; Tariot P; Murphy DL; Weingartner H; Mueller EA; Cohen RM
    Psychopharmacology (Berl); 1985; 87(2):247-9. PubMed ID: 3931154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
    Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of acute scopolamine in geriatric depression.
    Newhouse PA; Sunderland T; Tariot PN; Weingartner H; Thompson K; Mellow AM; Cohen RM; Murphy DL
    Arch Gen Psychiatry; 1988 Oct; 45(10):906-12. PubMed ID: 3048225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations.
    Sunderland T; Tariot PN; Newhouse PA
    Brain Res; 1988 Dec; 472(4):371-89. PubMed ID: 3066441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic modelling of Alzheimer's disease.
    Sunderland T; Tariot PN; Weingartner H; Murphy DL; Newhouse PA; Mueller EA; Cohen RM
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):599-610. PubMed ID: 3541054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral, and physiologic responses.
    Little JT; Johnson DN; Minichiello M; Weingartner H; Sunderland T
    Neuropsychopharmacology; 1998 Jul; 19(1):60-9. PubMed ID: 9608577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.
    Martinez R; Molchan SE; Lawlor BA; Thompson K; Martinson H; Latham G; Weingartner H; Sunderland T
    Biol Psychiatry; 1997 Jan; 41(1):50-7. PubMed ID: 8988795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.
    Broocks A; Little JT; Martin A; Minichiello MD; Dubbert B; Mack C; Tune L; Murphy DL; Sunderland T
    Biol Psychiatry; 1998 Mar; 43(6):408-16. PubMed ID: 9532345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia.
    Wesnes K; Anand R; Lorscheid T
    Acta Psychiatr Scand Suppl; 1990; 360():71-2. PubMed ID: 2248080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed.
    Flicker C; Serby M; Ferris SH
    Psychopharmacology (Berl); 1990; 100(2):243-50. PubMed ID: 2305013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of scopolamine on matching to sample paradigm and related tests in human subjects.
    Koller G; Satzger W; Adam M; Wagner M; Kathmann N; Soyka M; Engel R
    Neuropsychobiology; 2003; 48(2):87-94. PubMed ID: 14504417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys.
    Callahan MJ; Kinsora JJ; Harbaugh RE; Reeder TM; Davis RE
    Neurobiol Aging; 1993; 14(2):147-51. PubMed ID: 8487917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRH attenuates scopolamine-induced memory impairment in humans.
    Molchan SE; Mellow AM; Lawlor BA; Weingartner HJ; Cohen RM; Cohen MR; Sunderland T
    Psychopharmacology (Berl); 1990; 100(1):84-9. PubMed ID: 2104988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans.
    Vitiello B; Martin A; Hill J; Mack C; Molchan S; Martinez R; Murphy DL; Sunderland T
    Neuropsychopharmacology; 1997 Jan; 16(1):15-24. PubMed ID: 8981385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study.
    Agnoli A; Martucci N; Manna V; Conti L; Fioravanti M
    Clin Neuropharmacol; 1983; 6(4):311-23. PubMed ID: 6661730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties.
    Kennedy DO; Wake G; Savelev S; Tildesley NT; Perry EK; Wesnes KA; Scholey AB
    Neuropsychopharmacology; 2003 Oct; 28(10):1871-81. PubMed ID: 12888775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central cholinergic pathway involvement in the regulation of pupil diameter, blink rate and cognitive function.
    Naicker P; Anoopkumar-Dukie S; Grant GD; Neumann DL; Kavanagh JJ
    Neuroscience; 2016 Oct; 334():180-190. PubMed ID: 27531858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine.
    Fredrickson A; Snyder PJ; Cromer J; Thomas E; Lewis M; Maruff P
    Hum Psychopharmacol; 2008 Jul; 23(5):425-36. PubMed ID: 18421801
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.